Seventure Partners predicts bright future for microbiome opportunities

Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture capitalist’s EUR 160 billion fund will prosper from the increased understanding of human and microbe interactions. Seventure has just published a report on the emergence of the microbiome as an intense area of interest in the biotech industry, starting with the advent of deep sequencing technology in the early 2000s and moving toward the Phase II trials in progress now.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Eric de la Fortelle – Venture Partner, Seventure Partners